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Aims: This study aims to quantify drug-metabolising enzymes, transporters, receptor
tyrosine kinases (RTKs) and protein markers (involved in pathways affected in cancer)
in pooled healthy, histologically normal and matched cancerous liver microsomes
from colorectal cancer liver metastasis (CRLM) patients.
Methods: Microsomal fractionation was performed and pooled microsomes were
prepared. Global and accurate mass and retention time liquid chromatography–mass
spectrometry proteomics were used to quantify proteins. A QconCAT (KinCAT) for
the quantification of RTKs was designed and applied for the first time. Physiologically
based pharmacokinetic (PBPK) simulations were performed to assess the contribu-
tion of altered abundance of drug-metabolising enzymes and transporters to changes
in pharmacokinetics.
Results: Most CYPs and UGTs were downregulated in histologically normal relative
to healthy samples, and were further reduced in cancer samples (up to 54-fold). The
transporters, MRP2/3, OAT2/7 and OATP2B1/1B3/1B1 were downregulated in
CRLM. Application of abundance data in PBPK models for substrates with different
attributes indicated substantially lower (up to 13-fold) drug clearance when using
cancer-specific instead of default parameters in cancer population. Liver function
markers were downregulated, while inflammation proteins were upregulated (by up
to 76-fold) in cancer samples. Various pharmacodynamics markers (e.g. RTKs) were
altered in CRLM. Using global proteomics, we examined proteins in pathways rele-
vant to cancer (such as metastasis and desmoplasia), including caveolins and collagen
chains, and confirmed general over-expression of such pathways.
Conclusion: This study highlights impaired drug metabolism, perturbed drug trans-
port and altered abundance of cancer markers in CRLM, demonstrating the impor-
tance of population-specific abundance data in PBPK models for cancer.
K E YWORD S
colorectal cancer liver, metastasis, drug-metabolizing enzymes, inflammation, metastasis,
PBPK, proteomics, QconCAT, receptor tyrosine kinases, transporters
The authors confirm that the Principal Investigator for this paper is Amin Rostami-Hodjegan and that he had direct clinical responsibility for patients.
Received: 22 July 2021 Revised: 14 September 2021 Accepted: 16 September 2021
DOI: 10.1111/bcp.15098
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Br J Clin Pharmacol. 2021;1–13. wileyonlinelibrary.com/journal/bcp 1
1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common type of cancer
worldwide,1 with half of patients having liver metastasis.2 Surgical re-
section is the ideal intervention for colorectal cancer liver metastasis
(CRLM), but this is not always possible and other adjuvant therapies
(e.g. chemotherapy) are available.3 Because liver metastasis is com-
mon, pharmacokinetics (PK) of many drugs differ in CRC patients due
to perturbed system parameters.4–8 Despite the fact that a constant
dosage is often used throughout the cancer chemotherapy, there are
temporal changes in pharmacodynamic (PD) targets with disease pro-
gression or remission. The proteomic nature of these changes has not
been well studied with respect to altered expression of drug targets
during cancer progression,9 which has been reported across different
cancer types.10
To translate the effects of changes in expression under disease
conditions to in vivo outcomes, proteomics data are used within the
framework of in vitro to in vivo extrapolation linked to physiologically
based PK (PBPK)/PD modelling.11,12 However, protein abundance
data are limited in cancer populations. The limited qualitative data
available on CRLM on the expression of drug-metabolising enzymes
(DMEs)13 suggest that cancer may alter drug metabolism. Quantitative
transporter data in CRLM are limited to mRNA measurements14 or
comparison of expression in livers from healthy donors with that in
histologically normal livers from CRLM patients.15 Expression of
pharmacodynamic targets including receptors is also affected by
cancer. Of particular interest are receptor tyrosine kinases (RTKs),
which regulate cellular processes and many anticancer drugs, such as
regorafenib, inhibit them, thus improving survival of CRLM
patients.16,17 RTK mRNA and protein expression data have been
measured in cell lines18–20 but human studies are only limited to
immunohistochemistry.21–24
This study, therefore, aimed to apply global and QconCAT-based
proteomics to quantify PK and PD proteins in pooled liver samples
from healthy (healthy donors), histologically normal (peri-carcinoma-
tous) and matched cancerous liver tissue from CRLM patients. The
target proteins are involved in drug metabolism, transport and path-
ways affected in cancer. Notably, we designed, for the first time, a
QconCAT standard (KinCAT) for absolute quantification of RTKs. We
additionally assessed the contribution of altered abundance using
PBPK models. The generated abundance data will fill key gaps in cur-
rent knowledge about human enzymes, transporters and PD targets
in CRLM.
2 | METHODS
2.1 | Liver samples and donor characteristics
Matched cancerous and histologically normal liver tissues from adult
CRLM patients were supplied by the Manchester University NHS
Foundation Trust (MFT) Biobank, Manchester, UK, following hepa-
tectomy. Ethics were covered under the MFT Biobank generic
ethical approval (NRES 14/NW/1260 and 19/NW/0644). Healthy
human liver microsomal samples (tumour-free) from healthy subjects
were collected postmortem and provided by Pfizer (Groton, CT,
USA), and prepared previously by Vitron (Tucson, AZ, USA) and BD
Gentest (San Jose, CA, USA). Ethical approval was obtained by the
suppliers. Tables S1 and S2 present demographic and clinical
information.
2.2 | QconCATs standards
MetCAT and TransCAT standards have been used in this study, as
described previously.25,26 A modified version of the TransCAT was
used (Supplementary Information). KinCAT is a novel QconCAT for
the quantification of human RTKs. It consists of concatenated tryptic
peptides representative of the following proteins: macrophage
colony-stimulating factor 1 receptor (CSF1R), epidermal growth factor
receptor (EGFR), ephrin type-A receptor 2 (EPH2A), erythroblastic
oncogene B2 (ERBB2), fibroblast growth factor receptors (FGFR1/2/
3), FMS-like tyrosine kinase (FLT3), insulin-like growth factor 1 recep-
tor (IGF1R), insulin receptor (INSR), mast/stem cell growth factor
receptor (KIT), hepatocyte growth factor receptor (MET), neuro-
trophic tyrosine kinase receptor type 2 (NTRK2), platelet-derived
growth factor receptors (PGFRA/B), proto-oncogene tyrosine-protein
kinase receptor (RET), angiopoietin-1 receptor (TIE2), tyrosine-protein
kinase receptor UFO (AXL), vascular endothelial growth factor recep-
tors (VGFR1/2/3). These proteins were selected for their crucial role
What is already known about this subject
• Enzymes and transporters are perturbed in different
cancer types, and thus, pharmacokinetics of drugs is
affected in cancer patients.
• Various pharmacodynamic markers and targets involved
in biological pathways are also affected.
• Quantitative perturbation data are not available for colo-
rectal cancer liver metastases (CRLM).
What this study adds
• Expression of proteins involved in liver drug metabolism
and disposition is impaired in CRLM.
• Expression of pharmacology markers (e.g., receptor tyro-
sine kinases) changes in CRLM, leading to perturbations
in biological pathways (metastasis and angiogenesis).
• Altered abundance of enzymes and transporters affects
predicted drug clearance in CRLM patients.
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in cancer biology and treatment. Details are provided in Supplemen-
tary Information and Figure 1.
2.3 | Sample preparation for proteomics
Liver tissue samples were fractionated to microsomes,8 as described
in Supplementary Methods. Pooled samples were made up by com-
bining equal volumes of individual microsomes from either 15 healthy
samples (HP), 16 histologically normal samples (NP) from CRLM
patients or 16 matched cancerous liver samples (TP) from the same
CRLM patients. Each pooled sample (70 μg) was spiked with known
amounts (Supplementary Methods) of each isotopically-labelled
QconCAT, and prepared using filter-aided sample preparation.27–29
Samples were denatured (sodium dexoycholate, 10% w/v final con-
centration), reduced (dithiothreitol, 0.1 M final concentration),
alkylated (iodoacetamide, 100 μL of 50 mM) and digested (2 doses of
LysC 2% w/w, 30C, 4 h, and trypsin 4% w/w, 37C, 16 h).30
Unlabelled peptide standards, GVNDNEEGFFSAR, VGFLPDGVIK and
SEGVNDNEEGFFSAR, were added to quantify the QconCATs
(MetCAT, TransCAT and KinCAT, respectively). Samples were lyophi-
lized by vacuum centrifugation after sample preparation and stored at
20C until mass spectrometric (MS) analysis. Additional details are
provided in Supplementary Methods.
2.4 | Liquid chromatography and tandem MS
Dried samples were re-suspended (3% acetonitrile-0.1% formic acid)
and loaded onto an UltiMate 3000 Rapid Separation liquid chroma-
tography (LC) system (Dionex Corporation, Sunnyvale, CA, USA)
coupled to a Q Exactive HF Hybrid Quadrupole-Orbitrap MS (Thermo
Fisher Scientific, Waltham, MA, USA). Details are provided in Supple-
mentary Methods.
F IGURE 1 Design and characterization of the KinCAT. Liquid chromatography–mass spectrometry traces of peptides included in the KinCAT
sequence (A). SDS-PAGE gel showing the expression and purity of KinCAT; M = molecular weight marker (B). Sequences of KinCAT peptides and
the RTK proteins they represent (C). Sequence coverage of the KinCAT protein, showing complete expression (D). Incorporation efficiency of 13
C6-lysines (K) and arginines (R) in the KinCAT peptides (E)
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2.5 | Analysis and annotation of proteomic data
Proteomic data were processed using MaxQuant 1.6.7.0 (Max Planck
Institute, Martinsried, Germany), and searched against a customized
database, comprising human UniprotKB database (74 788 sequences)
and QconCAT sequences. For targeted accurate mass and retention
time (AMRT) analysis, light-to-heavy intensity ratios were used with
QconCAT concentrations to calculate protein amounts based on
accurate mass and retention time for each peptide.27,31 Peptides
selected for quantification of CYPs/UGTs, transporters and RTKs are
presented in Tables S6, S7 and S8, respectively. For global analysis,
data were processed using the total protein approach (TPA) based
on the ratio of individual protein to total proteome MS signal
intensity.32
2.6 | Physiologically-based pharmacokinetic
(PBPK) simulations
The effect of abundance of DMEs and transporters on simulated
plasma drug clearance was assessed using PBPK modelling on Simcyp
V20 Release 1 (Certara, Sheffield, UK) on 50 substrates with different
attributes and hepatic extraction ratios. The compound files were
available in Simcyp library (Table S5), and PBPK simulations used sys-
tem parameters available on the simulator for healthy and cancer
populations. The effects of abundance changes (based on TPA) in
CRLM were assessed using previously described models8:
Model 1 (Healthy): default microsomal protein per gram of liver
(MPPGL) and abundance levels for the healthy population (Simcyp).
Model 2 (Cancer-D): default MPPGL and abundance for the cancer
population (Simcyp).
Model 3 (New Cancer-ALN): MPPGL of histologically normal tissue8
and abundances of DMEs and transporters in histologically normal
relative to healthy tissue were used for the cancer population,
assuming the whole liver is histologically normal (maximum meta-
bolic capacity).
Model 4 (New Cancer-ALC): MPPGL of cancerous tissue8 and
abundance of DMEs and transporters in tumour relative to healthy
tissue were used for the cancer population, assuming the whole
liver is cancerous (minimum metabolic capacity) and liver mass is
unchangeable.
The relative ratios of the clearance (CL) were compared.
2.7 | Data analysis
Ratios were calculated for abundances in histologically normal and
tumour samples relative to healthy control samples. Expression levels
with ratios within 2-fold (0.5–2.0) were considered similar. Graphs
were generated using GraphPad Prism 8.1.2 (GraphPad Software, La
Jolla, CA, USA).
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, and
are permanently archived in the Concise Guide to PHARMACOLOGY
2019/20.33,34
3 | RESULTS
All results were based on 3 pooled samples made up of healthy,
histologically normal and tumour tissue. Each measurement was
duplicated and found to be consistent (within a factor of 2 in all but
3 cases of enzymes; Table S9). A single value-not an average is
reported here.
3.1 | Novel QconCAT (KinCAT) for the
quantification of kinases
Kinases regulate cellular processes and are involved in the develop-
ment and progression of cancer. Kinase expression has not previously
been quantified by mass spectrometry-based methods in human tis-
sue. We have therefore designed a QconCAT (KinCAT) to quantify
RTKs (Figure 1A and C). The KinCAT, including N-terminal core ribo-
somal protein to improve expression of the KinCAT30 with a histidine
tag for purification, migrated on SDS-PAGE (molecular mass 82 kDa),
demonstrating that the intact QconCAT was expressed (Figure 1B).
This was confirmed by Mascot sequence coverage (88%; Figure 1D).
The 13C-labelling efficiency was >97% (Figure 1E). The LC–MS traces
of the digested KinCAT peptides are shown in Figure 1A, using Sky-
line (version 19.01.193; www.sciex.com/products/software/skyline-
software). More details about the KinCAT are provided in the
Table S4.
3.2 | Abundance of enzymes and transporters in
healthy, histologically normal, and cancerous liver
3.2.1 | Absolute abundance of CYP and UGT
enzymes
The effect of cancer on the expression of DMEs was evaluated by
comparing the expression in 1 pooled healthy (HP), 1 pooled histo-
logically normal (NP) and 1 pooled tumorous sample (TP) from CRLM
patients using accurate mass and retention time. With the exception
of CYP2J2, protein expression of CYPs (Figure 2A) and UGTs
(Figure 2D) in healthy tissue is similar to that in normal. Abundances
of CYPs and UGTs in HP ranged from 0.16 to 90.2 and 7.7 to
60.7 pmol/mg microsomal protein, respectively. Interestingly,
enzyme expression was significantly decreased for all CYPs and
UGTs in tumour (Figure 2A and D). In healthy tissue, the most abun-
dant CYPs are reported to be CYP2E1 and CYP3A428 as here.
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Interestingly, CYP2C9 was the most abundant (17.4 pmol/mg micro-
somal protein) in tumour, followed by 2E1, and 3A4 (9.5 and
9 pmol/mg, respectively). The most abundant UGT was UGT2B7 in
all samples but whereas histologically normal tissue showed
80.9 pmol/mg and healthy 60.7 pmol/mg, this fell to 9.1 pmol/mg in
tumour. CYP2D6, UGT1A3 and CYP3A5 were not detected in all
samples in the targeted analysis so are discussed below in TPA
analysis.
3.2.2 | Abundance distribution of CYPs and UGTs
in HP and TP
The pie charts in Figure 2 represent the abundance distribution
(based on targeted analysis) of CYPs (Figure 2B and C) and UGTs
(Figure 2E and F) in HP and TP. This visualization clearly shows the
dominance of CYP2C9 (30%) in tumour against CYP3A4 (28%) in
healthy tissue.
3.2.3 | Fold change in the expression of CYPs and
UGTs in TP and NP relative to HP
The targeted approach is generally considered to be the gold standard
in accuracy but is restricted to proteins for which both standard and
analyte are detected. We therefore further analysed the data using
the total protein approach, which is untargeted. In Figure 2G and H,
the abundances of enzymes in NP and TP are expressed relative to
HP. Most of the CYPs in NP were within 2-fold of levels in HP, except
CYP3A4 and CYP3A5 (3-fold lower in NP), and CYP2J2 (5-fold lower
in NP). Most of UGTs however were downregulated by more than
2-fold (up to 7-fold for UGT1A1) in NP. Both CYPs and UGTs were
dramatically downregulated in tumour ranging from 4 (CYP2C9) to
54-fold (CYP2B6).
The relative quantification by the 2 methods was in broad
agreement. The TPA permits the quantification of many more pro-
teins at the expense of the precision we obtain with the targeted
approach.
F IGURE 2 Protein expression of cytochrome P450 enzymes (CYPs) and UDP-glucuronosyltransferases (UGTs) in healthy (HP), histologically
normal (NP) and tumorous (TP) pooled hierarchical linear modelling samples. Absolute abundance of CYPs (A) and UGTs (D) is expressed in pmol/
mg of microsomal protein. Pie charts represent the distribution of CYPs (B, C), and UGTs (E, F) in HP and TP, respectively, based on their absolute
abundance. The relative changes in expression of CYPs (G) and UGTs (H) in NP and TP compared with HP. The green and red arrows indicate
increased and decreased expression relative to HP, respectively. The dotted line represents 2-fold change
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3.2.4 | Abundance of transporters in healthy,
histologically normal and cancerous liver
Expression of ABC and SLC transporters, plasma membrane protein
(ATP1A1) and cadherin-like transporter (CDH17) was measured
using AMRT targeted method (Figure 3A and B). The QconCAT per-
mits the quantification of 7 ABC transporters, which were detected
in healthy and histologically normal samples. BCRP, MRP6 and BSEP
fell below the limit of quantification in tumour and 3 others (MDR3,
MRP2 and MRP3) were also much reduced (Figure 3A). P-gp alone
of the ABC transporters rose in TP (0.71 and 0.46 pmol/mg protein
in TP and HP). ATP1A1 was moderately abundant in healthy liver, as
indicated previously,28 and its abundance was higher in cancer
(16.3 pmol/mg in TP and 7.3 pmol/mg in HP). CDH17 was only
quantifiable in NP and TP. Expression of SLCs was perturbed in
cancer, with significantly lower abundance of OAT7, OATP2B1,
OATP1B3, OATP1B1 and OAT2 in TP (0.25, 0.69, 0.36, 0.54 and
0.16 pmol/mg, respectively) compared with HP (3.3, 2.4, 2.4, 2.0 and
1.5 pmol/mg, respectively).
3.2.5 | Untargeted relative quantification of
transporters
The TPA is able to quantify OCT3 and MRP4 for which there were no
standards (Figure 3C and D). MRP4 was hardly changed, but OCT3
was significantly reduced in cancer. As expected, the other trans-
porters followed the same trends as the targeted analysis.
3.2.6 | Differential protein abundance of non-CYP
non-UGT and antioxidant enzymes
Figure 4A and B depict the relative changes in abundance of non-CYP
non-UGT DMEs (for which no labelled standards were available) using
the TPA. FMO4, ALDH2, SULT1A2, SULT1B1, ADH4, ADH6, ADH1B
and AOXA were more abundant in NP compared with HP, whereas
CES3, POR, MGST2 and MGST3 were less abundant (>2-fold change).
The suppressive effect of cancer on expression was observed with
CES1/2, FMO3/5, MGST1/2/3, POR, MGST1/2/3, ALDH1A/1G,
F IGURE 3 Abundance of transporters in healthy (HP), histologically normal (NP) and tumorous (TP) pooled hierarchical linear modelling
samples. Absolute abundance of ABC transporters, plasma membrane marker (ATP1A1) and 1 adhesion protein (CDH17; A) and solute carriers
(SLCs; B), expressed in pmol of protein/mg of total protein. Relative change in expression of ABC (C) and SLC (D) transporters in NP and TP,
compared with HP. The green and red arrows indicate increased and decreased expression relative to HP, respectively. The dotted line represents
2-fold change
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ADH6, ADHX, EPHX1 and SULT2A1, with up to 7.3-fold lower levels
(tumour vs. healthy).
The abundances of antioxidant enzymes are summarised in
Figure 4C. Haem-oxygenase 1 (HMOX1) was observed at 70-fold
lower abundance in histologically normal samples compared with
healthy and was below the limit of quantification in the tumour. By
contrast, peroxiredoxin PRDX2 was expressed at higher levels in
normal (20-fold) and tumour (>12-fold) livers compared with healthy.
HMOX1 catabolizes haem, and has antiapoptotic and anti-
inflammatory functions.35 PRDX2 induces cancer cell proliferation
and protects from reactive oxygen species-induced cell damage and
apoptosis.36
3.3 | Assessment of changes in expression of
kinases in normal and tumour compared with healthy
tissue
3.3.1 | Expression levels of receptor tyrosine
kinases
To assess the expression of RTKs, AMRT targeted analysis using
KinCAT was carried out (Figure 5A). Expression of VGFR1, TIE2,
FGFR3, ERBB2 and IGF1R was higher in NP relative to HP, whereas
AXL and VGFR3 were less abundant in NP, and RET was exclusively
detected in NP (at 0.04 pmol/mg protein). Compared with HP, expres-
sion levels of INSR, EGFR and AXL were lower, and those of NTRK2,
ERBB2 and IGF1R were higher in TP. KIT was only expressed in NP
and TP. FGFR1 (0.01 pmol/mg), VGFR2 (0.02 pmol/mg), FGFR2
(0.04 pmol/mg), and PGFRB (3.8 pmol/mg) were exclusively detected
in TP.
3.3.2 | Other kinases exclusively detected in
tumour
Figure 5B shows additional kinases involved in various biological path-
ways that were exclusively detected in TP, including creatine kinases,
mitogen-activated protein kinase, STRAP, PAK1 and GAK.
3.3.3 | Fold change in expression of RTKs between
HP to NP and TP
Fold changes in the abundance of RTKs were assessed by the TPA
(Figure 5C). The most striking results were: (i) raised levels of KIT,
F IGURE 4 Relative abundance of non-CYP non-UGT enzymes (A, B), and antioxidant enzymes (C) measured in healthy (HP), histologically
normal (NP) and tumorous (TP) pooled hierarchical linear modelling samples. The green and red arrows indicate higher or lower expression
relative to HP, respectively. The dotted line is set to 2-fold change. (A) ALDH, aldehyde dehydrogenase; CES, carboxylesterase; FMO, flavin-
containing monooxygenase; MGST, microsomal glutathione S-transferase; POR, NADPH-cytochrome P450 reductase. (B) ADH, alcohol
dehydrogenase; AOX, aldehyde oxidase; EPHX, epoxide hydrolase; SULT, sulfotransferase. (C) CAT, catalase; HMOX, haem-oxygenase; PRDX,
peroxiredoxin; SOD, Superoxide dismutase
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VGFR2 and EPHA2 in tumour relative to both histologically normal and
healthy; and (ii) decreased levels of TIE2, EGFR, FGFR2 and INSR in
tumour. The pattern of expression in histologically normal tissue is less
clear-cut for these but in all cases was decreased relative to healthy.
3.3.4 | RTK-related pathways affected in cancer
Figure 5D summarizes the roles of RTKs in terms of functional path-
ways (tumour cell survival/proliferation, angiogenesis, differentiation/
apoptosis, and extracellular matrix formation/metastasis). There is evi-
dence of increased expression of non-RTKs related to cell survival and
proliferation and extracellular matrix formation. Interestingly, STAT1
increases, and STAT3/6 decrease in tumour—both these proteins are
involved in differentiation and apoptosis. Overall, proteins involved in
tumour cell survival, proliferation and metastasis were dysregulated in
cancerous livers.
3.4 | Abundance of markers of liver function,
inflammation, desmoplasia (fibrosis) and metastasis
By applying the TPA, we assessed fold changes in the abundance of
various markers of liver function and conditions induced by cancer in
NP and TP relative to HP.
3.4.1 | Liver function
The liver function markers alanine aminotransferase, alkaline phospha-
tase and aspartate aminotransferase are reported to be increased in
the plasma in many cancer patients.37 Figure 6A shows that in livers
all 3 appeared to be decreased (up to 7.6-fold). This may suggest
enhanced secretion rather than enhanced production of these
markers in cancer.
F IGURE 5 Abundance of kinases in healthy (HP), histologically normal (NP) and tumorous (TP) pooled hierarchical linear modelling.
(A) Absolute abundance of receptor tyrosine kinases (RTKs), expressed in pmol of protein/mg of liver microsomal protein using KinCAT as
standard. (B) Relative abundance of kinases (not RTKs) exclusively identified in TP, expressed as ppm (parts/million) using the total protein
approach. (C) Relative change of RTKs in NP and TP compared with HP. When a bar is not present, this means that there was no change in NP or
TP compared with HP. The crosses indicate the absence of a protein from a sample. The green and red arrows indicate increased and decreased
expression relative to HP, respectively. The dotted line is set to 2-fold change. (D) Functions of RTKs (targeted by anticancer tyrosine kinase
inhibitors, TKIs) and biological pathways that are affected by the altered abundances of RTKs. Green and red arrows show increased and
decreased abundance of proteins in TP, respectively. The blue line represents exclusive expression (low) in HP, and red font means the target was
not detected in any of the samples
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3.4.2 | Inflammation
Figure 6B shows modest changes in interferon-induced transmem-
brane protein 3 and catenin β-1 but huge upregulation of interleukin
enhancer-binding factor-2: 76-fold in tumour and above 30-fold in
histologically normal adjacent to tumour. interleukin enhancer-binding
factor-3, macrophage migration inhibitory factor, arachidonate
5-lipoxygenase and nuclear factor-κB were detected in tumour but
below the limit of detection in healthy tissue.
3.4.3 | Desmoplasia
We also measured desmoplasia markers (Figure 6C) involved in the
growth of fibrous tissue. Consistent with fibrotic appearance of the
tumorous samples observed during tissue fractionation, we detected
glutathione peroxidase (GPX)3, GPX8 and tenascin exclusively in
TP. Additionally, GPX4 and caveolins1 and 2 were expressed at higher
levels (>2-fold) in TP compared with HP.
3.4.4 | Metastasis markers
Expression of metastasis markers was perturbed in CRLM. As
expected, collagen chains were massively upregulated in the tumour
samples (Figure 6D)—COIA1 and COEA1 were >1000-fold higher
than in the healthy samples and COCA1 and COC4A1 were
undetectable in the healthy samples. Interestingly, the histologically
normal samples also showed high levels of COIA1 and COEA1—165
times the levels observed in the healthy samples. Cathepsins
(Figure 6E) were generally unchanged across all samples, with only
CATG being significantly higher (9.9-fold) in TP relative to HP. Other
F IGURE 6 Relative change of markers of liver function (A), inflammation (B), desmoplasia (C), collagen chains (metastasis markers; D),
cathepsins (metastasis markers; E), and other metastasis markers (F) in histologically normal (NP) and tumorous (TP) compared with healthy (HP).
HP is set to 1 and NP and TP are expressed as relative changes to HP. When a bar is not present, this means that there was no change of
expression in NP or TP relative to HP. The crosses indicate absence of a protein from a sample. The green and red arrows indicate increased and
decreased expression relative to HP, respectively. The dotted line is set to 2-fold change
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metastasis markers were also significantly upregulated in tumour sam-
ples (see Figure 6F). These proteins have proteolytic function, facili-
tating matrix degradation and tumour cell invasion.
3.5 | PBPK simulations
The Simcyp simulator contains PBPK models for various drugs in
healthy and disease populations. The cancer population is not well
defined and systems data such as measured here could improve these
models. MPPGL data were previously used to update current PBPK
models.8 In addition to the MPPGL data, abundance data obtained
here were used to refine the Simcyp PBPK models. Simulations for
50 substrates with different attributes and hepatic extraction ratios
were performed (Figure 7). Four populations were used: the default
healthy and cancer populations, and 2 constructed using the data
obtained here. New Cancer-ALN uses data from the histologically nor-
mal sample assuming the data apply to the whole liver. New Cancer-
ALC similarly uses data pertaining to the tumour sample. Ratio of the
clearance predicted using New Cancer-ALC was >2-fold lower (up to
13-fold) than that obtained using the default Cancer-D model for
33 out of 50 drugs simulated.
4 | DISCUSSION
For the first time, this study applied targeted and global LC–MS/MS-
based proteomics to quantify DMEs, transporters and PD targets
(including RTKs, inflammatory markers, metastatic markers) in healthy,
histologically normal and cancerous livers from CRLM patients. For
the proteins investigated here, no quantitative data have been
reported previously in CRLM. Our experimental data were used to
optimise PBPK models in cancer population (Simcyp) in order to
assess the impact of the changes in abundance on PK.
CYPs and UGTs were significantly downregulated in cancer tissue,
highlighting that the clearance of CYP-substrates may be significantly
lower in patients with late-stage liver cancer. Abundances of CYPs
and UGTs were also lower in histologically normal tissue, meaning that
the impact of cancer is not limited to the tumour, but affects the meta-
bolic function of a larger amount of the liver. Additional DMEs such as
F IGURE 7 Relative ratios of the clearance
(CLs) of drugs in Healthy (black), Cancer-D (grey)
and New Cancer-ALN (white) to New Cancer-
ALC populations. Healthy: default abundances
of enzymes and transporters (Simcyp) with a
healthy population. Cancer-D: default
abundances of enzymes and transporters
(Simcyp) with a cancer population. New Cancer-
ALN: abundance of enzymes and transporters
measured in this study for histologically normal
tissue with a cancer population. New Cancer-
ALC: abundances of enzymes and transporters
measured in this study for cancer tissue with a
cancer population. The green rectangle shows
the drugs with <2-fold change in drug CL than
that obtained using the New Cancer-ALC model,
the amber shows 2–5-fold higher CL than that
obtained using the New Cancer-ALC model, and
the red shows >5-fold higher CL than that
obtained using the New Cancer-ALC model
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ADHs and FMO3 were downregulated in tumorous tissue, suggesting
impaired capacity in almost all drug clearance pathways. Expression of
antioxidant enzymes was decreased in tumours and adjacent, histolog-
ically normal tissue, suggesting impaired detoxification in CRLM. In
agreement with our findings, proteomics and activity data from hepa-
tocellular carcinoma patients showed a significant impact of cancer on
CYPs, UGTs, ADHs, FMO3 and SULTs.5,38–40
Transporters are important for the disposition of drugs and the
trafficking of nutrients and metabolites. Abundance data on trans-
porters showed significant changes in expression in CRLM, suggesting
impaired disposition. The majority of SLC transporters were down-
regulated in cancerous tissue. Efflux transporters, MRP2 and MRP3,
which are involved in drug resistance, were downregulated in histo-
logically normal and tumorous tissue, while other efflux transporters,
such P-gp and MRP4, were increased in cancer tissue. This is a prelim-
inary finding, which, if reproduced in individual tumours, could have
implications for choice of therapy in CRLM. The lower expression of
OATPs and OCT1 is consistent with data from hepatocellular carci-
noma patients, whereas changes in BCRP, MRPs and P-gp were not
consistent.7 Such differences are not surprising considering differ-
ences in the cancer type. This reflects the need to model each cancer
type separately.
The protein expression levels of RTKs is reported for the first
time in this study. Our approach employed a novel QconCAT as a
standard for these low abundance proteins. However, we also con-
ducted global measurements simultaneously using the TPA for quanti-
fication. In general, the targeted measurements are more sensitive
and more accurate but restricted to a relatively small number of pro-
teins. In both histologically normal and cancerous tissue from CRLM
patients, expression of FGFR2 and INSR was downregulated, while
that of KIT and VGFR2 upregulated. TIE2 and EGFR were down-
regulated and EPHA2 upregulated in cancerous livers. The altered
expression of these proteins renders them potential diagnostic or
therapeutic biomarkers in CRLM. Platelet-derived growth factor
receptor (PGFRB) was highly and exclusively detected in tumorous tis-
sue, consistent with literature suggesting PGFRB is a metastasis
marker.24 Desmoplasia markers were upregulated in CRLM patients,
indicating extensive growth of fibrous tissue. Consistent with previous
findings,41 expression of collagen chains was significantly higher in
CRLM. The observed perturbations of kinases and cancer-related pro-
teins in CRLM suggests a potential effect on cancer-related pathways,
such as cell survival/proliferation, angiogenesis, differentiation and
metastasis.42 In the current study, these markers (such as PI3K,
mTOR, Ras, Raf, ERK, SRC and RAC1) were affected in CRLM. As
pathophysiological changes can affect protein expression, these pro-
teins can be used as potential markers for monitoring disease progno-
sis and as therapeutic targets. However, it should be noted that all
these targets are measured at the time when the patients were going
through surgery: it may be possible using recently described analysis
of floating RNA in plasma to plot temporal changes from early diagno-
sis to the point of patient requiring surgery.43
Global proteomic data revealed reduced expression of liver func-
tion markers and upregulation of inflammatory markers in cancer.
Arachidonate 5-lipoxygenase and nuclear factor-κB, were exclusively
detected in cancer tissue, and these constitute important targets for
anti-inflammatory drugs.44 The severity of inflammation in cancer
affects the production of cytokines and increases oxidative stress,
which leads to perturbations in proteins involved in drug metabolism
and disposition and can subsequently alter drug PK in cancer
patients.45
To assess the impact of the observed changes in expression of
DMEs and transporters on drug PK, we performed PBPK simulations
on substrates with different attributes and hepatic extraction levels.
Decreased clearance of anticancer drugs in cancer patients has been
reported previously.46–48 In our previous study,8 we assessed the
effect of experimentally-derived MPPGL values in CRLM on PK by
optimising and updating an existing cancer population in the Simcyp
simulator. In the current study, we further updated the cancer popu-
lation with abundance data for DMEs and transporters. The changes
in abundance levels affected drug clearance for most of the drugs
under study. With the assumption that the whole liver is tumorous
(New Cancer-ALC model), lower drug clearance was predicted com-
pared with a histologically normal liver (New Cancer-ALN model).
The PBPK simulations show that appropriate abundance data in com-
bination with appropriate MPPGL scalar values may improve PK pre-
dictions, particularly when used with the appropriate percentage of
cancerous liver tissue. Clinical data for the simulated drugs in CRLM
were not available and we only assessed the impact of change in
abundance of DMEs and transporters on PK. Further simulations
could verify these updated PBPK cancer models, when clinical data
become available.
In conclusion, our data begin to address key gaps in knowledge
about human protein abundance in cancer. DMEs were significantly
downregulated and transporters were perturbed in CRLM. In addition,
RTKs were altered in CRLM, leading to perturbations in biological
pathways relevant to cancer development and progression. These
data may be valuable for proposing diagnostic and therapeutic
markers. Liver function was also impaired and inflammation markers
were upregulated in CRLM. Desmoplasia and metastasis markers were
highly expressed in cancer samples. PBPK simulations on 50 substrates
revealed lower drug clearance (up to 13-fold) when using cancer
population-specific abundance data. Our study suggests that appro-
priate abundance values for CRLM may be used to refine PK
predictions.
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